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ABSTRACT 
 
Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, 
maximal tolerated dose (MTD), dose limiting toxicities (DLTs), pharmacokinetics, 
pharmacodynamics and preliminary clinical activity of pictilisib (GDC-0941), an oral, 
potent and selective inhibitor of the Class I phosphatidylinositol-3-kinases (PI3K). 
 
Patients and Methods: Sixty patients with solid tumors received pictilisib at 14 dose 
levels from 15 to 450mg once-daily, initially on days 1-21 every 28 days and later, 
utilizing continuous dosing for selected dose levels. Pharmacodynamic studies 
incorporated 18F-FDG-PET, and assessment of phosphorylated AKT and S6 
ribosomal protein in platelet-rich plasma and tumor tissue.  
 
Results: Pictilisib was well-tolerated. The most common toxicities were grade 1-2 
nausea, rash and fatigue while the DLT was grade 3 maculopapular rash (450mg, 2 
of 3 patients; 330mg, 1 of 7 patients). The pharmacokinetic profile was dose-
proportional and supported once-daily dosing. Levels of phosphorylated serine-473 
AKT were suppressed >90% in platelet rich plasma at 3 hours post-dose at the MTD 
and in tumor at pictilisib doses associated with AUC >20uM.hr. Significant increase 
in plasma insulin and glucose levels, and >25% decrease in 18F-FDG uptake by PET 
in 7 of 32 evaluable patients confirmed target modulation. A patient with V600E 
BRAF mutant melanoma and another with platinum-refractory epithelial ovarian 
cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial 
response by RECIST and GCIG-CA125 criteria, respectively.  
 
Conclusion: Pictilisib was safely administered with a dose-proportional 
pharmacokinetic profile, on-target pharmacodynamic activity at dose levels ≥100mg 
and signs of antitumor activity. The recommended Phase II dose was continuous 
dosing at 330mg once-daily. 
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TRANSLATIONAL RELEVANCE  
The Phosphatidylinositol-3-kinase (PI3K) pathway is one of the most commonly 
deregulated in cancer and is currently a major focus for anticancer drug 
development. This manuscript describes the first-in-man phase I trial of pictilisib 
(GDC-0941), one of the very first pan-class I selective PI3K inhibitors evaluated in 
patients with advanced cancer. Pictilisib demonstrated a favorable pharmacokinetic 
profile and was well tolerated at biologically active doses. Comprehensive 
pharmacodynamic biomarker evaluation showed suppression of AKT and S6 
phosphorylation in platelet rich plasma and tumor, together with significant changes 
in plasma insulin and glucose levels, and decreases in 18F-FDG uptake by PET. In 
addition, anti-tumor activity is reported in patients with PI3K pathway deregulation. 
These results provide the basis for further evaluation of pictilisib in rationally 
designed monotherapy or combination trials. In addition, this phase I trial of pictilisib 
exemplifies the use of 'Pharmacological Audit Trail' guidelines for molecularly 
targeted therapy in cancer. 
 
 
 
INTRODUCTION 
 
Phosphatidylinositol-3-kinase (PI3K) regulates processes involved in the hallmark 
traits of cancer, such as cell growth, survival, metabolism, invasion and metastases.1 
Multiple isoforms of PI3K exist in mammalian cells and these isoforms are 
subdivided into three classes based on structural features and lipid substrate 
preferences.1 The Class IA isoforms (p110α, β and δ) are responsible for the 
production of the second messenger phosphatidyl-inositol-3,4,5 triphosphate 
(PIP3).2,3 PI3K activation initiates a signal transduction cascade, of which the major 
effectors are the kinases AKT and mTORC1.4 PTEN is a tumor suppressor gene 
which functions as a phosphatase, and is the primary negative regulator of PI3K, 
through hydrolysis of PIP3.5 Deregulation of the PI3K pathway has been frequently 
implicated in a wide range of malignancies, including glioma, prostate, breast, 
ovarian and endometrial cancer.6 Alteration of the pathway commonly occurs 
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through mutation or amplification of PIK3CA which encodes the p110α catalytic 
subunit, loss of function of PTEN (through deletion, mutation or reduced expression), 
alterations in the INPP4B and PHLPP phosphatases, mutations of the PI3K 
regulatory subunits encoded by PIK3R1 and PIK3R3, or through activation of 
upstream receptor tyrosine kinases or crosstalk with the RAS pathway.3,6,7 
 
Pictilisib (GDC-0941; Genentech Inc., South San Francisco, CA) is an oral, potent, 
selective pan-inhibitor of class I PI3K (IC50 against purified recombinant human PI3K 
isoforms: p110α=3 nM, p110β=33 nM, p110δ=3 nM, p110γ=75 nM) with 193-fold 
less activity against mTOR compared to p110α.8 Antitumor activity was 
demonstrated in human tumor xenograft murine models; at an oral dose of 
150mg/kg, pictilisib achieved 98% and 80% growth inhibition in PI3K pathway-
activated U87MG glioblastoma and IGROV1 ovarian cancer xenografts, 
respectively.9 At this dose level, pictilisib achieved plasma concentrations in tumor 
tissue >GI50-antiproliferative concentrations for >8 hours and demonstrated 
downstream PI3K pathway biomarker changes such as time- and dose-dependent 
inhibition of phosphorylation of AKT (Ser473) and P70S6 kinase (Thr421/Ser424).9 
These data led us to conduct a first-in-human Phase I dose-escalation study of 
pictilisib in patients with advanced solid tumors to evaluate safety and tolerability, 
define dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of 
pictilisib administered orally. Secondary objectives included characterization of 
pharmacokinetics, assessment of pharmacodynamics including changes in tumor 
18F-fluorodeoxyglucose (18F-FDG) uptake (by positron emission tomography [PET] 
studies), tumor expression of phosphorylated (Ser235/Ser236) S6 ribosomal protein 
(phospho-S6) in mandatory pre- and on-treatment biopsies and phosphorylated 
(Ser473) AKT (phospho-AKT) in platelet-rich plasma (PRP), and preliminary 
evaluation of antitumor activity. 
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PATIENTS AND METHODS 
This single-center trial was conducted in accordance with the Declaration of Helsinki 
at The Royal Marsden NHS Foundation Trust (London, UK) after approval by local 
institutional review boards. Informed consent from all patients was obtained.  
 
Eligibility  
Patients aged ≥18 years with histologically confirmed solid tumors and no 
conventional treatment option were eligible. Other inclusion criteria included: fasting 
serum glucose ≤120mg/dl, HbA1c ≤upper limit of normality, prior chemotherapy or 
radiotherapy completed ≥4 weeks previously, toxicity from prior therapy resolved to 
grade ≤1, an Eastern Cooperative Oncology Group performance status ≤1, expected 
life expectancy ≥12 weeks and adequate organ functions. Significant exclusion 
criteria included diabetes mellitus requiring medication, significant respiratory 
disease (requiring supplemental oxygen or predicted diffusion capacity of carbon 
monoxide [DLCO] ≤50%), and use of anticoagulation or chronic corticosteroid. 
 
Study Design 
This was an open-label, single-centre, Phase I study utilizing a modified 3+3 dose-
escalation design. During dose escalation, the dose of pictilisib was doubled until 
drug-related toxicity of grade ≥2 was observed. Dose escalations from this point 
were limited to ≤50% of the previous dose (if grade ≤2) or 33% in the event of grade 
≥3 toxicities.  
 
Pictilisib was administered on day 1, followed by a 1-week washout to evaluate 
single-dose pharmcokinetics and pharmacodynamics. Dosing was once-daily for 21 
or 28 days every 28 days (21/28 or 28/28 schedule, respectively). The 
recommended starting dose in humans of 15mg once-daily was chosen based on 
the no observed adverse effect level and MTD in 28-day rodent and dog species 
studies. The 21/28 starting schedule was chosen to implement a drug-free period to 
allow recovery from acute toxicities and limit cumulative toxicities to maximize the 
administered dose of pictilisib. A continuous dosing schedule (28/28) was 
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implemented to further explore safety and pharmacodynamics of dose levels 330-
400mg. 
 
Definitions of DLT and MTD 
DLTs were based on toxicities observed in the first cycle and assessed by the 
investigator as possibly related to pictilisib. A DLT was defined as grade 4 
neutropenia for >5 days or accompanied by fever >38.5oC, grade 4 
thrombocytopenia or grade 3 non-hematologic toxicity of any duration with the 
exception of alopecia. Grade 3-4 nausea, vomiting and diarrhea were only 
considered DLTs if they occurred despite optimal medical management. Grade ≥3 
total bilirubin, AST, ALT were considered DLTs except when pre-existing Grade 1 
values and were <7.5x ULN due to known liver metastases.  Decreases in DLco 
≥20% were also considered DLTs.   The MTD was defined as the highest dose at 
which ≤1 of 6 DLTs (<33%) patients experienced DLT at that dose level. 
 
Safety and Efficacy  
Clinical and laboratory assessments were conducted at baseline and weekly 
thereafter. Safety assessments included medical history, physical examination, 
electrocardiogram, hematology, biochemistry (including fasting glucose and HbA1C,), 
and assessment of pulmonary toxicity with pulse oximetry, DLCO, and high resolution 
CT (HRCT) of the chest. Adverse events were graded using CTCAE (Common 
Toxicity Criteria for Adverse Events) version 3.0. Tumor assessments were 
performed at the end of cycles 1 and 2, and then every 2 cycles using RECIST 
guidelines.10  
 
Pharmacokinetics 
Plasma levels of pictilisib were determined from samples collected on day 1: pre-
dose, and 0.5, 1, 2, 3, 4, 8, 24, 48 and 72 hours post-dose; and on day 15: pre-dose, 
and 0.5,1,2,3,4,8, and 24 hrs post-dose. Pharmacokinetic samples for pictilisib were 
analyzed using a validated HPLC/MS/MS method. Standard pharmacokinetic 
parameters were determined using a non-compartmental method (WinNonlin version 
5.2.1; Pharsight Corporation, Mountain View, CA) 
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Pharmacodynamics 
Platelet-rich plasma was obtained from patients pre-dose, and at 1, 3, 8, 24 hours 
post-dose on days 1 and 15 of cycle 1 for analysis of phospho-AKT (Ser473) using an 
electrochemiluminescense assay (Luminex xMAP, Luminex Corp, Austin, TX). 
Wherever feasible, patients underwent tumor biopsies pre-treatment and 1-4 hours 
post-dose on day 15; samples were fixed, sectioned and stained with haematoxylin 
and eosin, and for phospho-S6 using anti-phospho-S6 (Ser235/236) (Cell Signaling 
Technology Inc., Beverly, MA), or anti-phospho-AKT (Serine 473) clone D9E (Cell 
Signaling Technology).  Plasma was obtained pre-dose and at 1 hour post-dose on 
cycle 1 day 1 for analysis of glucose and insulin levels at dose levels ≥100mg. Whole 
body 18F-FDG-PET scans were performed at baseline, 1-4 hours post-dose between 
day 22 and the end of cycle 1 as well as between day 50 and the end of cycle 2.  
 
PI3K pathway alteration biomarkers  
PIK3CA mutations were identified in circulating tumor plasma DNA (ctDNA) using a 
site-specific molecular characterization protocol.11 Archival and fresh tumor samples 
were analyzed using the SEQUENOM® OncoCarta Panel (Sequenom Inc., San 
Diego, CA). PIK3CA amplification was assessed by fluorescence in-situ hybridization 
(FISH) and PTEN status by immunohistochemistry.12  
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RESULTS 
Patient characteristics 
Sixty patients with confirmed progressive cancer at study entry were enrolled, most 
of whom were heavily pre-treated (median of 3 prior systemic therapies [range 0-16)] 
(Table 1). All patients were included in the safety analysis. 
 
Treatment & dose escalation 
Sixty patients were treated in 14 dose-schedules (Table 2). Dose escalation on the 
21/28 schedule proceeded through 11 dose levels from 15mg. At 450mg, 2 of 3 
patients experienced DLTs. The dose level of 330mg was then evaluated with 1 DLT 
observed in 7 patients treated at this dose level on a 21/28 schedule. Subsequently, 
the dose levels of 330mg, 340mg and 400mg on the 28/28 schedule were assessed.  
 
DLTs and MTD 
The MTD was exceeded at 450mg once-daily (21/28 schedule) with a DLT of grade 
3 rash in 2 patients. This was a maculopapular rash covering 70-80% of the body 
surface area that presented approximately 2 weeks after commencement of daily 
pictilisib dosing and resolved spontaneously 2 weeks after treatment discontinuation. 
At 330mg once-daily (21/28 schedule), the grade 3 maculopapular rash observed in 
1 of 7 patients had a similar temporal pattern of onset and resolution; this was also 
declared as a DLT. On the 28/28 schedule, no DLT was observed. 
  
Safety and tolerability 
Pictilisib was well-tolerated up to 330mg (21/28 schedule); most adverse events 
were mild to moderate in severity with no treatment-related deaths (Table 2). At the 
assessed dose levels, there did not appear to be a significant difference in the 
toxicity profile between the 21/28 and 28/28 schedules. Treatment-related adverse 
events that occurred in ≥10% of patients included: nausea, diarrhea, vomiting, 
fatigue, dysgeusia, decreased appetite and rash. In addition to the 2 DLTs of grade 3 
rash at the 450mg dose level, the third patient at this dose level experienced grade 2 
rash; nonetheless, this patient received 8 months of pictilisib with concomitant use of 
oral antihistamines and skin emollients. Of 10 patients treated with 330mg once-daily 
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(28/28 schedule), grade 1 or 2 rash was observed in 2 patients, and grade 3 rash 
(occurring after the DLT-defining window) in 2 patients; these similarly resolved with 
the introduction of drug holidays and supportive medications including emollients and 
corticosteroids.  
 
Other clinically-relevant drug-related adverse events ≥grade 3 were grade 4 
hyperglycemia (n=1, 130mg) and grade 3 pneumonitis (n=1, 340mg). The grade 4 
hyperglycemia was transient, unaccompanied by clinically significant symptoms, 
signs or acidosis, and occurred in a patient with cholangiocarcinoma and previous 
pancreatico-duodenectomy who started the use of low-dose prednisolone 2 days 
prior to the event. Grade 3 pneumonitis was observed at the end of cycle 1 in a 
breast cancer patient previously treated with chest radiotherapy who developed 
grade 1 dyspnea, reduced DLCO and a ground glass appearance on HRCT; these 
resolved following 2 weeks of drug interruption and concomitant use of prednisolone. 
When pictilisib was reintroduced at 240mg, the dyspnea and HRCT changes 
recurred; these subsequently resolved following permanent discontinuation of 
pictilisib due to disease progression.  
 
Pharmacokinetics 
Pharmacokinetic parameters of pictilisib were estimated for all dose cohorts and are 
summarized in Table 3 and Supplementary Table 1. Under fasting conditions, 
pictilisib was rapidly absorbed after oral administration (median Tmax of 2 hours 
[range 0.5-8]); this was independent of dose and was unchanged after multiple 
doses.  Terminal plasma elimination half-life (T1/2) on day 1 ranged between 13.1 
and 24.1 hours. Dose-proportional increases in exposure (Cmax and AUC0-24) was 
observed across the dose levels studied (Figure 1). Similar pharmacokinetic 
characteristics were seen on day 15. The accumulation index (AUCDay15/AUCDay1) 
ranged from 1.2 to 2.2, suggesting modest accumulation following multiple doses. 
 
Pharmacodynamics 
We observed a dose- and concentration-dependent decrease in phospho-AKT in 
platelet rich plasma on days 1 and 15 (Figure 2). Inhibition up to 90% of phospho-
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AKT level in platelet rich plasma was demonstrated 1 to 3 hours post-dose at the 
RP2D; this effect was sustained (50% of baseline) at 24 hours post-dose. 
Reductions in S6 and AKT phosphorylation in tumor biopsies was greatest at the 
highest exposure level of pictilisib (AUC >20uM.hr on day 15), with all three patients 
in this cohort showing ≥75% decrease in S6 phosphorylation and 2 patients also 
exhibiting a 100% decrease in AKT phosphorylation (Figure 3). Following pictilisib 
treatment at 330mg on cycle 1 day 1, there was a statistically significant increase in 
plasma insulin and glucose levels at 1 hour from baseline with mean fold-change 
(i.e. ratio of post- over pre-treatment level) in plasma insulin and glucose levels of 
3.58 (95%CI: 2.33-5.49) and 1.18 (95%CI: 1.10-1.26), respectively (Supplementary 
figure 1. 18F-FDG-PET imaging showed a reduction from baseline of 18F-FDG-tracer 
uptake at dose levels ≥45mg with an overall median change in maximum 
standardized uptake value (SUVmax) of -13% (range -47 to 22) (Supplementary 
figure 2). Seven of 32 evaluable patients (22%) achieved a metabolic partial 
response by EORTC-PET criteria (>25% reduction in mean SUVmax without new 
lesions) on 18F-FDG-PET.10  
 
Antitumor Activity 
One patient with BRAF V600E-mutated metastatic melanoma, but no detected PI3K 
pathway deregulation, achieved a confirmed RECIST-partial response; she received 
pictilisib at 330mg once-daily (21/28 schedule) for 9.5 months. She had previously 
been treated sequentially with paclitaxel and dacarbazine, but had not received a 
BRAF or MEK inhibitor. A heavily-pretreated, platinum-refractory advanced epithelial 
ovarian cancer patient with PIK3CA amplification (with high polysomy and >60% of 
tumor cells harboring 4 copies of PIK3CA) and loss of PTEN achieved radiological 
stable disease for 4 months with GCIG-CA125 partial response13 (Supplementary 
Figure 3) associated with 36% reduction in SUVmax on 18F-FDG-PET and 56% 
reduction in tumor phospho-S6 expression. A patient with cKIT exon 9 mutant 
gastrointestinal stromal tumor but no evidence of PI3K pathway deregulation 
achieved stable disease for 7.5 months on pictilisib 450mg once-daily, and this was 
associated with pharmacodynamic changes of 47% reduction in SUVmax on 18F-FDG-
PET and 75% reduction in tumor phospho-S6 expression.  
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Of 60 patients, 12 (20%) remained on study for >3 months and 2 (3%) for >6 
months. Supplementary Table 2 shows the pharmacokinetic-pharmacodynamic-
clinical relationship of patients who demonstrated a partial response by RECIST, 
GCIG-CA125 or 18F-FDG-PET EORTC criteria. 
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DISCUSSION 
In this first-in-human dose-escalation Phase I study, we confirm the feasibility of 
safely inhibiting Class I PI3K in patients with solid tumors. Pictilisib was well-
tolerated at doses shown here to modulate PI3K signaling in normal and tumor 
tissues, and demonstrated dose-proportional pharmacokinetics. The most common 
drug-related toxicities included grade 1-2 nausea, fatigue, diarrhea, vomiting, 
dysgeusia and reduced appetite. The RP2D of oral pictilisib was 330mg continuous 
once-daily dosing. Dose limiting toxicity was grade 3 maculopapular rash occurring 
in 2 of 3 patients treated at 450mg/day and 1 of 7 patients at 330mg/day. Our data 
indicate that the severity of the rash was not clearly related to higher exposures of 
pictilisib (Supplementary Figure 4) and resolved with discontinuation of pictilisib. 
The rash was maculopapular but not acneiform or blistering, did not show a 
predilection for sun-exposed areas, and was similar to the rash observed with other 
PI3K, AKT and mTOR inhibitors, thereby pointing to a mechanism-based toxicity.14-16 
Although this toxicity could be a potential pharmacodynamic biomarker of pictilisib, 
its underlying pathophysiology remains unclear and warrants further evaluation. 
 
Our study design incorporated the use of the ‘Pharmacological Audit Trail’ guidelines 
using appropriate pharmacokinetic-pharmacodynamic biomarkers.17,18 Our study 
design incorporated the use of the pharmacological audit trail guidelines using 
appropriate pharmacokinetic-pharmacodynamic biomarkers. The audit trail has been 
used by both academia19 and industry20 as a guideline to help answer critical ‘go/ no-
go’ decisions based on scientifically measurable and rigorous end points. This audit 
trail has utility in providing broad guidance of the drug development process, even 
though the same precise effects in preclinical models may not be exactly reproduced 
in patients, as demonstrated in this trial. The favorable preclinical PK properties of 
pictilisib were reproduced in this Phase I trial.9 Preclinical pharmacokinetic-
pharmacodynamic modeling based on MDA-MB-361, a human breast cancer 
xenograft with HER2 amplification and  PIK3CA 1633G>A mutation, predicted the 
minimal target plasma AUC to be 6uM*hr (3000 ng*hr/ml) in order to achieve ≥90% 
tumor growth inhibition; this target AUC was achieved in most patients treated at 
doses >80mg following one week of consecutive dosing and support the view that 
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pictilisib is associated with biologically meaningful activity at these dose levels and 
exposures, especially at the RP2D. Based on these preclinical data, we additionally 
postulated that ≥90% inhibition of AKT phosphorylation is needed to inhibit cancer 
cell proliferation.9,21 We demonstrate here a dose-response relationship between 
drug exposure and target modulation in normal tissue, with up to 90% decrease in 
AKT phosphorylation in platelet rich plasma at up to 3 hours post-dose at the RP2D. 
Whilst a direct correlation between pictilisib exposure and decrease in S6 and AKT 
phosphorylation in tumor is less clear, at the highest level of drug exposure (AUC 
>20uM/hr) there was clear evidence of pharmacodynamic effect, with >75% 
decrease in S6 phosphorylation and 100% reduction in AKT phosphorylation in 2 of 
3 patients. The lack of consistent target modulation in tumor at lower drug exposures 
contrasts with the consistent dose-response relationship in platelet-rich plasma and 
is possibly related to different assay conditions which likely favour greater inhibition 
in the latter, together with disparities in drug concentrations between normal and 
tumor tissues due to likely differences in tissue architecture and haemodynamics.  
Such differences highlight the complexity of accurately defining the pharmacokinetic-
pharmacodynamic relationship of molecularly targeted drugs, along with additional 
important issues including extrapolation of preclinical models to predict effects in 
patients, inter-patient variation due to host pharmacogenomic variation, intra-and 
inter-patient tumour heterogeneity, and differences in analytical 
sensitivity/methodology in platelet-rich plasma versus tumour biopsies. All of these 
are likely to be important, highlighting the importance of evaluating different 
pharmacodynamic biomarkers to increase confidence in the overall pharmacological 
effects of a drug within the audit trail framework, as we have done here. 
 
To this end, at the RP2D of 330mg we demonstrate multimodal pharmacodynamic 
evidence of target modulation including the reduction of 18F-FDG-PET tracer uptake, 
inhibition of phospho-AKT in platelet-rich plasma and phospho-S6 in tumor tissue as 
well as increase in plasma glucose and insulin levels. These pharmacodynamic 
changes were observed regardless of molecular genetic status and from dose levels 
≥100mg.  
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PI3K signaling regulates insulin sensitivity, and hyperglycemia has been predicted to 
be a hallmark toxicity of PI3K inhibition.6,22,23 However, pictilisib-related 
hyperglycemia was limited to grade 1-2 elevations in this study with grade ≥3 
hyperglycemia being observed in only 1 patient with an extrahepatic 
cholangiocarcinoma who had undergone a previous pancreatic resection and was 
commenced on a corticosteroid 2 days prior to the adverse event. We confirmed 
target and pathway modulation at the RP2D with observations of convincing 
pharmacodynamic changes in phospho-S6 and 18FDG-PET in tumor, and phospho-
AKT, glucose and insulin in plasma. Nonetheless, it is possible that homeostatic 
mechanisms via negative feedback loops may cause drug resistance and account 
for the lack of more significant hyperglycemia.  
 The toxicity profile of pictilisib is in contrast to BKM120 (another pan-Class I PI3K 
inhibitor) where rash, hyperglycemia and mood alterations were the observed 
DLTs.15 Apart from rash, the latter two were not significant toxicities of pictilisib. One 
would not have expected such differences if these DLTs are mechanism-based 
toxicities, especially when the observed in vitro potency of pictilisib is higher than 
that of BKM120.24 Pictilisib has a lower central nervous system (CNS) penetration 
than BKM120 while the targeted disruption of insulin signaling in the brain has been 
shown to lead to a diabetes mellitus phenotype.15,25-28  It is likely that the marked 
hyperglycemia observed with BKM120 is due to the synergistic inhibition of PI3K 
signaling in peripheral tissues (e.g. muscle and adipose tissues) with non-canonical 
insulin-targeted tissues (including the brain), and the lack of CNS penetration may 
have enhanced the clinical therapeutic index of pictilisib relative to BKM120.  The 
other pan-Class I PI3K inhibitors which have undergone Phase I clinical evaluation 
include SAR245408 and the irreversible wortmanin derivative PX-866.29,30 Both 
drugs were associated with minimal hyperglycaemia but differences were observed 
in the frequency of rash, which occurred in 26% of patients treated with SAR245048 
(all grades) and in none of the patients treated with PX-866. The importance of the 
therapeutic window of the pan-Class I inhibitors with regards to their 
pharmacodynamic effect is critical, and in this respect our hypothesis that ≥90% 
inhibition of AKT phosphorylation is needed to inhibit cancer cell proliferation reveals 
potentially important differences between pictilisb and the other drugs in this class, 
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with SAR245048 reporting a 40-80% reduction in tumor AKT phosphorylation, in 
comparison to pictilisib achieving 100% AKT inhibition in twp patients at the MTD.  
There is currently no validated predictive biomarker for PI3K pathway inhibitors. 
Somatic mutational sequencing and assessment of PTEN expression status were 
therefore undertaken. Our results highlight ongoing difficulties in the attempt to 
identify predictive biomarkers for pan-Class I PI3K inhibitors, with no clear 
relationship between PI3K mutation/amplification or PTEN expression status and 
response to pictilisib.3 In this trial, PI3K pathway alterations were identified in 9 of 60 
patients (15%), comprising 3 PTEN negative; 1 PTEN negative and PIK3CA 
amplification by FISH; and 5 PIK3CA mutations. Of these, none achieved a RECIST-
based response and only 1 achieved a response by GCIG-CA125 criteria. This 
suggests the prediction of sensitivity may require more complex biomarker 
signatures rather than single mutational events.3,21 Additionally, an association 
between 18F-FDG-PET changes and RECIST response was not detected, in keeping 
with results from an earlier study of mTOR inhibitors.31 
 
We note the modest response rates in this trial and therefore, whilst we postulate 
that ∼90% inhibition of AKT phosphorylation for several hours is needed to inhibit 
cancer cell proliferation based on our preclinical tumor phosphorylation data9 the 
exact duration and magnitude to which the pathway should be inhibited remains 
unclear and more work is required to relate the extent of downstream 
phosphoprotein biomarker modulation to efficacy in patients. We also believe that 
important distinctions should be made between the utility of reduction in AKT 
phosphorylation as a pharmacodynamic and predictive biomarker of response. The 
best RECIST-responder in this study bore a BRAF V600E mutant melanoma with no 
demonstrable PI3K mutation; she achieved a radiological partial response by 
RECIST and remained on pictilisib for 9.5 months (she was not previously treated 
with a BRAF inhibitor and this was not therefore a withdrawal response). Responses 
to PI3K pathway inhibitors have been reported in BRAF mutated cancer cell lines, 
including those without any known PI3K pathway aberration.32 Although these 
cancer cell lines are primarily dependent on RAS-RAF-MEK-ERK signalling for their 
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proliferation, they are likely to have a degree of co-dependence on the PI3K-AKT 
pathway for their proliferation and survival, possibly explaining the response to 
pictilisib in this patient. In addition, there may be other activating effects in the PI3K 
pathway that we have been unable to assess that predispose to sensitivity including 
potential immunomodulatory effects given that T cell receptor signalling involves the 
PI3K pathway.33 
 
An increasing understanding of potential resistance mechanisms21 and promising 
preclinical data from combinatorial use of pictilisib34-36 has led to clinical trials of 
pictilisib in combination with drugs including erlotinib, fulvestrant, trastuzumab 
emtansine (Kadcyla®), GDC-0973 (a MEK inhibitor), paclitaxel, and chemotherapy 
regimens comprising paclitaxel/bevacizumab, carboplatin/paclitaxel/bevacizumab, 
and cisplatin/pemetrexed. Results from these ongoing studies are awaited. 
 
In summary, pictilisib was safely tolerated at doses up to the RP2D which is 330mg 
once-daily administered continuously. Displaying favorable pharmacokinetic 
properties, the plasma exposure levels achieved with ≥80mg once-daily dosing were 
consistent with those associated with effective target modulation and antitumor 
activity predicted by preclinical in vivo pharmacokinetic-pharmacodynamic modeling. 
Analysis of pharmacodynamic biomarkers in peripheral blood and tumor tissue 
crucially provided evidence of significant PI3K pathway modulation at the RP2D. 
There is also evidence of clinical antitumor activity.  Overall, these data provide 
strong support for the continued clinical evaluation of pictilisib. 
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Figure Legend 
 
Figure 1. Pharmacokinetic profile of pictilisib.  
(A) Plasma concentration versus time profile for all dose levels.  
(B) Maximum plasma concentration (Cmax) versus dose  
(C) area under the curve (AUC) versus dose. Solid and dashed lines represent the 
fitted regression lines for days 1 and 15, respectively 
 
Figure 2:  
(A) Percentage change in levels of phosphorylated AKT (pAKT) in platelet-rich 
plasma (PRP) and plasma level of pictilisib up to 24 hours following administration of 
pictilisib (at RP2D of 330mg) on days 1 and 15 of cycle 1 (n=8). 
(B) Pictilisib concentration-dependent inhibition of phosphorylated AKT (pAKT) in 
platelet-rich plasma (PRP) following systemic exposure to pictilisib. Data represent 
available concentration-matched PRP pAKT inhibition from duration of Phase I 
investigation 
 
Figure 3. Pharmacodynamic analysis in tumor biopsies.  
 
(A) Phospho-S6 (pS6) and phospho-AKT (pAKT) levels in baseline and on-treatment 
paired tumor biopsies grouped according to AUC0-24 (hr*uM) on day 15. pS6 
staining levels were measured using a standard H-Score method, and pAKT staining 
levels were measured using a validated, qualitative scoring method (represented on 
y axis). Pre- and on-treatment samples from the same patient were stained in the 
same experiment and examined blind. Arrows indicate patient 50036.  
(B) Immunohistochemistry images of pS6 and pAKT from patient 50036.  
(C) Percent change from baseline of pS6 and pAKT levels. Tumor biopsies for three 
patients were not evaluable for phospho-AKT and are indicated with an “x”. All 
patients received doses of >60mg of pictilisib with the exception of patient 50008 
who received 45 mg. 
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Table 1. Demographics and clinical characteristics of all treated patients.  
Characteristic 
All patients 
No. of 
patients % 
Sex 
  Male 
  Female 
 
30 
30 
 
50 
50 
Age, years 
  Median 
  Range 
 
59 
27-77
ECOG performance status at screening 
  0 
  1 
 
28 
32 
 
47 
53 
Primary cancer diagnosis 
  Colorectal  
  Breast 
  Soft tissue sarcoma 
  Melanoma   
  Ovarian     
  Gastric 
  Prostate 
  Others 
 
16 
9 
7 
5 
3 
2 
2 
16 
 
27 
15 
12 
8 
5 
3 
3 
27 
No. of prior lines of systemic therapies 
  Median 
  Range 
 
3 
0 - 16 
 
Abbreviation: ECOG: Eastern Cooperative Oncology Group 
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Table 2. Summary of adverse events (AEs).  
AEs possibly or likely treatment-related that occurred in ≥10% of patients according to maximum grade for each patient by dose 
level and grade. AEs grades ≥3 are presented in separate columns for each dose-schedule only when observed. 
Dose level (mg)  15 30  45  60 80   100  130   180  245  330  450 330  340  400 All 
Schedule 21/28 21/28 21/28 21/28 21/28 21/28 21/28 21/28 21/28 21/28 21/28 28/28 28/28 28/28 21 or 28/28 
No. of patients 4 3 4 4 3 5 3 3 3 7 3 10 7 1 60 
Toxicity grade All  All  All  All  All  All  ≥3 All  All  All  ≥3 All  ≥3 All  ≥3 All  ≥3 All  All  ≥3 All 
Any adverse event 2 1 2 2 3 3 1 1 2 3 2 7 2 3 2 10 2 6 1 9 46 
                      
Gastrointestinal                      
    Nausea 1 0 0 2 1 3 0 0 0 1 0 4 0 2 0 9 0 4 1 0 28 
    Diarrhea 0 0 2 1 1 1 0 0 1 2 0 3 0 0 1 7 0 1 0 1 19 
    Vomiting 0 0 0 2 1 0 0 0 0 0 0 3 0 2 0 3 0 4 0 0 15 
    Decreased appetite 0 0 0 0 0 0 0 0 1 1 0 2 0 1 0 6 0 3 0 0 14 
    Dysgeusia  1 0 1 0 1 0 0 0 1 0 0 1 0 1 0 5 0 2 0 0 13 
                      
Skin & mucosa                       
    Rash* 0 0 0 0 0 0 0 0 1 0 1 4 2 3 2 4 0 1 1 5 14 
    Stomatitis** 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 2 1 0 7 
    Xeroderma  0 0 0 0 0 0 0 0 0 1 0 2 0 1 1 4 0 0 0 1 8 
                      
Constitutional                      
    Fatigue 0 0 0 0 2 1 0 0 1 1 0 4 0 2 0 6 0 3 1 0 21 
*Including preferred terms of rash, rash maculo-papular, rash macular, rash pruritic, rash erythematous, and rash papular. 
** Including preferred terms of stomatitis, mucosal inflammation, mouth ulceration. 
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 Table 3. Key pharmacokinetic parameters of pictilisib on days 1 and 15. 
  Elimination half-life (hr) Tmax (hr) Cmax (µM) AUC 0-24 (hr*µM) 
Day 1 No. of patients Geometric mean Median Range Geometric mean Geometric mean 
15 mg QD 4 19.2 2 1-2 0.112 0.978 
30 mg QD 3 24.1 2 1-2 0.144 1.18 
45 mg QD 4 19.5 2 2 0.362 2.77 
60 mg QD 4 18.8 2 1-2 0.242 2.02 
80 mg QD 3 20.1 2 1-2 0.632 5.45 
100 mg QD 5 14.6 2 1-8 0.362 3.19 
130 mg QD 3 13.1 2 1-2.5 0.359 2.99 
180 mg QD 3 17.1 2 2-3 0.611 5.95 
245 mg QD 3 16.8 2 1-2 0.994 8.18 
330 mg QD 17 15.7 2 0.5-8 1.52 14.4 
340 mg QD 7 20.9 2 1-4 1.68 14.9 
400 mg QD 1 14.8 2 2 1.65 15.6 
450 mg QD 3 15.0 2 1-2 1.95 13.9 
Day 15       
15 mg QD 4  1.5 1-4 0.116 1.35 
30 mg QD 3  1 0.5-4 0.179 1.90 
45 mg QD 4  2 2 0.436 4.09 
60 mg QD 3  3 2-4 0.27 2.78 
80 mg QD 3  3 3-4 0.779 9.86 
100 mg QD 3  2 1-3 0.751 5.64 
130 mg QD 3  1 1-2 0.457 5.03 
180 mg QD 3  1 1-3 0.783 8.25 
245 mg QD 3  1 1-3 1.37 11.3 
330 mg QD 17  3 0-8 2.07 22.8 
340 mg QD 6  1 1-4 1.95 16.5 
450 mg QD 3  2 1-3 2.64 23.5 
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Figure 1 
Pictisilib Cmax versus Dose Pictisilib AUC versus Dose
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